Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
Managed Care August 2007	Managed Care Outlook Specialty drugs increasingly used to treat chronic conditions.
Managed Care July 2006	Specialty Anti-Inflammatories See Huge Increase in Utilization Americans spent 34% more for specialty anti-inflammatory agents used to treat rheumatoid arthritis in 2005 than any other specialty drug category.
The Motley Fool June 12, 2006 Brian Gorman	Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note.
Pharmaceutical Executive April 1, 2011	Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help.
The Motley Fool April 8, 2004 Brian Gorman	Genentech's Healthy Showing The company's first-quarter results were impressive, driven by pricey cancer drugs.
Managed Care September 2005 John Carroll	Plans Struggle for Control of Specialty Pharma Costs Biotech drugs are a quickly growing component of health plan budgets. Here are the latest management techniques.
Managed Care June 2006 John Carroll	When New Drugs Are Costly, How High to Raise Copays? As some pretty costly, yet very useful, drugs are introduced, will new formulary designs deny access to needy patients?
The Motley Fool April 7, 2011 Brian Orelli	Drug Approved! But Where's the Name? AstraZeneca prepares to cash in on a minuscule market.
CIO September 26, 2013 Stephanie Overby	Big Data Project Cuts Prescription Costs Express Scripts analytics portal helps doctors prescribe more cost-effective medicines.
The Motley Fool February 28, 2011 Brian Orelli	Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool March 4, 2005 Tom Taulli	In the Express Scripts Lane Express Scripts' strong results bring a much-needed lift to health-care investors.
The Motley Fool March 23, 2010 Brian Orelli	No Patent! No Generics? Take Advantage of the Situation Enjoy it while it lasts, pharma.
The Motley Fool May 26, 2011 Brian Orelli	Congress Sets Bad Precedent With AVANIR What happened to free markets?
Managed Care February 2005	Biggest increases in specialty drug costs seen in rheumatologic, cancer, and hemophilia agents Medco reports that of the top seven contributors to specialty drug costs, agents for rheumatologic conditions (80.6 percent), cancer (33.2 percent), and hemophilia (28.4 percent) demonstrated the greatest percent change in cost from 2002 to 2003.
Pharmaceutical Executive November 1, 2012 Lauri Mitchell	Who Pays for Specialty Medicines? Providers and patients fish for that delicate balance between access and abandonment.
The Motley Fool November 17, 2006 Brian Lawler	Genentech Gets Another Approval Today, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages. Investors, take note.
Pharmaceutical Executive November 1, 2014 Jill Wechsler	Outrage Grows Over Drug Pricing Insurers, physicians attack high-cost therapies in anticipation of specialty drug surge.
The Motley Fool February 26, 2011 Brian Orelli	FDA Applications and a Look Ahead It isn't pretty.
The Motley Fool July 30, 2010 Brian Orelli	A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
Chemistry World September 7, 2015	Cancer Drugs Fund axes 23 treatments The Cancer Drugs Fund, which covers the cost of some cancer treatments that are not currently available on the National Health Service, has cut 23 treatments -- involving 16 drugs.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool August 24, 2011 Brandon Glenn	Cardinal Health Sees Opportunity (but Faces Challenges) in Specialty Drugs Is Cardinal up for the challenge?
Managed Care September 2005	Biologics Trend Leads Pharmaceuticals The general stabilization in per-capita medical claims cost -- what services cost the health plan before the member is charged -- for the managed care industry has not, for the most part, spilled over to biologics, according to a survey.
The Motley Fool September 30, 2010 Brian Orelli	Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers.
The Motley Fool July 12, 2010 Ryan McBride	Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009.
Pharmaceutical Executive September 1, 2013 William Looney	Trying to Control Pharma Costs? A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, life altering diseases.
BusinessWeek January 21, 2010 John Carey	Making Personalized Medicine Pay Medco and other pharmacy benefit managers say future profits depend on matching drugs to patients based on their genes.
The Motley Fool May 31, 2011 Brian Orelli	Profit From This Growing Drug Trend Cancer drugs press on.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
Managed Care September 2006 Martin Sipkoff	Specialty Pharmacy Grows As Cost-Control Option As the population ages, specialty pharmacy is becoming a unique, profitable, and invaluable delivery system. Plans are increasingly turning to specialty pharmacies to provide the expertise they lack.
Pharmaceutical Executive February 1, 2012 Ben Comer	Best to Market Pharm Exec's Brand of the Year: Abbott's Humira
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool July 21, 2010 Brian Orelli	Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
Chemistry World January 13, 2011 Andrew Turley	UK tilts towards appraisal of Avastin as eye drug The UK is moving closer to opening up the National Health Service to cancer drug Avastin (bevacizumab) for the treatment of eye conditions, such as age-related macular degeneration.
BusinessWeek May 27, 2010 Pettypiece & Gibson	Training the Immune System to Fight Cancer Bristol-Myers' new melanoma drug may be a "game changer."
The Motley Fool May 18, 2010 Brian Orelli	Pfizer Double-Dips Is this the best way to go after multiple indications? The drugs are already approved or have been in the clinic for other indications; thus the double-dipping.
Pharmaceutical Executive February 1, 2014 Jill Wechsler	Drug Coverage, Costs Under Scrutiny Benefits offered by insurance plans on health exchanges and through Medicare are raising concerns about patient access to needed therapies
Managed Care August 2004 Alan Lotvin	Specialty Pharmacy Presents Unique Set of Challenges Only a small percent of a typical health plan's population takes medicine for conditions outside the generalist's scope. But it's a big portion of the drug bill.
The Motley Fool February 22, 2011 Brian Orelli	A Billion-Dollar Market to Open "Very Soon" Biosimilar drugs are finally coming to the U.S.
Pharmaceutical Executive June 9, 2014 Kleinrock & Noor	Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative.
The Motley Fool March 4, 2010 Brian Orelli	A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan.
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool September 23, 2008 Brian Lawler	Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released.
The Motley Fool February 13, 2009 Brian Orelli	The Easy Way to Develop Drugs Merck buys a pipeline of follow-on biologics and a building to produce them.
The Motley Fool August 10, 2004 Brian Gorman	Biotech Cost Control Will the high cost of therapies slow sales in the sector? Investors can avoid problems by paying close attention to companies' pipelines and reimbursement trends.
The Motley Fool July 30, 2010 Brian Orelli	3 Development-Stage Drugmakers Worth Watching A basket of potential drugs in just one company.